KROS•benzinga•
Truist Securities Maintains Buy on Keros Therapeutics, Lowers Price Target to $43
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 23, 2024 by benzinga